Shares of Human Genome Sciences (NASDAQ:

) have surged around 3.29% to $29.53. Volume has been heavy with around 2 million HGSI shares already trading hands on the session. Over the last 3-months, HGSI shares have gained nearly 10%. Human Genome Sciences (HGS) is a commercially focused biopharmaceutical company. The Company has three products in late-stage clinical development: BENLYSTA for systemic lupus erythematosus (

), ZALBIN for chronic hepatitis C, and raxibacumab for inhalation anthrax.